Advertisement

Topics

Companies Related to "Glucose Dependent Insulinotropic Receptor Protein Coupled Receptor GPR119" [Most Relevant Company Matches] RSS

02:24 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "Glucose Dependent Insulinotropic Receptor Protein Coupled Receptor GPR119" found in our extensive corporate database of over 50,000 company records.

Showing "Glucose Dependent Insulinotropic Receptor Protein Coupled Receptor GPR119" Companies 1–25 of 1,200+

Extremely Relevant

PanVera Corporation

Protein Kinase C Assays Androgen Receptor, Ligand Binding Domain Estrogen Receptor-Beta 1, Long Form Tau Protein, microtubule-associated protein, histidine-tagged Cytochrome P450 Monoclonal Antibodiesa broad selection of antibodies can be found here.


Receptor BioLogix

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of protein therapeutics called Intron Fusion Proteins™ (IFP™) to treat cancer, autoimmune, metabolic and other diseases.

Receptor BioLogix, Inc.

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of protein therapeutics called Intron Fusion Proteins™ (IFP™) to treat cancer, autoimmune, metabolic and other diseases.


ConfometRx

ConfometRx is pioneering a platform of structure-based drug development tools that facilitate target validation, lead identification, and lead optimization for G protein coupled receptor (GPCR) targets. This platform includes biochemical and biophysical technologies for defining drug binding sites; the production of pure, functional GPCRs for high-resolution structure determination by crystallogra...

Receptos, Inc.

Receptos is a biopharmaceutical company developing best- and first-in-class G protein-coupled receptor (GPCR) therapeutic candidates through information-driven drug discovery, including GPCR structure determination. The company’s lead program is a best-in-class S1P1 small molecule, agonist candidate for autoimmune indications, including multiple scler...

Angstrom Pharmaceuticals Incorporated

Ångstrom Pharmaceuticals, Inc. was formed in 1996 to add a new dimension to drug discovery. It is committed to discovering drugs that block the docking of an extracellular regulatory protein (ligand) to its receptor found on the outside of a cell – when this event is responsible for initiating a disease state. Receptors can be identified that trigger several intractable diseases including cance...

Receptor Biology Incorporated

Receptor Biology Inc. produce cloned receptors for pharmacology studies and drug discovery, products include adenosine, cannabinoid, dopamine, muscarinic, serotonin, opoid, bradykinin, transporter, wild type.

Synaptic Pharmaceutical Corporation

Synaptic Pharmaceutical Corporation is a biotechnology company engaged in the development of a broad platform of enabling technology which it calls "human receptor- targeted drug design technology." The Company is utilizing this technology to discover and clone the genes that code for human receptor subtypes that may be associated with specific disorders. The Company and its collaborative part...

Relevant

Athenagen, Inc

Athenagen, Inc., located in South San Francisco, is engaged in the development of small-molecule drugs that act on the nicotinic acetylcholine (nACh) receptor pathway. The company's lead nACh receptor agonists and antagonists are being developed to treat diseases associated with enhanced or impaired angiogenesis and in diseases where cognitive deficit plays a significant role. Athenagen currently ...

Ascent Scientific

Ascent Scientific offers a range of high quality receptor ligands and synthetic chemistry services at prices so low that as many researchers as possible will be able to afford them. The Low-Cost Ligand range includes receptor ligands and signalling tools in research areas such as glutamate, GABA, ion channels, cannabinoids, opioids, 5-HT and more. The Low-Cost Chemistry Service provid...

Lundbeck Research USA, Inc.

Now that scientists have mapped the human genome, new opportunities exist for developing drugs that exclusively target specific receptors associated with the symptoms and causes of a disease.Receptor-specific drugs provide a new model in drug discovery that can improve the state-of-the-art treatment for many serious and common disorders. Lundbeck Research USA uses this discovery model to pursue n...

Bio Balance Incorporated

BIO BALANCE INC., a New York corporation, founded in 1993, is engaged in studies of biomedical problems. The Company applies its experience in computational chemistry, molecular modeling, pharmacology and biochemistry to such specific areas of specialization as: Specific Formulations to Prevent Receptor Desensitization Molecular Modeling Construction of 3-Dimensional (3D) Models of Proteins Comput...

BTI

BTI has been manufacturing growth factor (GF) and attachment factor (AF) products since 1981. Our extensive product line includes receptor-grade, aseptically packaged GFs and AFs. These are highly purified proteins that have been membrane filtered, aseptically filled and lyophilized. Most BTI GFs have been tested in cell culture, receptor binding studies and in immunoassays. Some GFs are availa...

Escient Pharmaceuticals

Escient Pharmaceuticals is a privately held biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Focused on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-...

REMD Biotherapeutics, Inc.

REMD Biotherapeutics is a privately held, clinical-stage biotechnology company focused on creating and developing innovative protein-based therapies to treat metabolic diseases and other serious illnesses. The Company was founded by two former Amgen research scientists and has facilities in Camarillo, California and Beijing China (Cosci-REMD Biotherapeutic...

Escient Pharmaceuticals, Inc.

Escient Pharmaceuticals is a privately held biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Focused on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-...

Evolutec Group plc

Evolutec discovers and develops novel biopharmaceuticals for allergic, anti-inflammatory and auto-immune diseases. Evolutec has progressed its lead therapeutic molecule, rEV131, a novel histamine binding protein, from discovery to completion of initial Phase II clinical trials in allergic conjunctivitis, rhinitis and ocular inflammation. Positive preclinical data has also been generated in asthma ...

Tokai Pharmaceuticals Inc.

Tokai Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. The company’s lead drug candidate, galeterone, is a highly selective, multi-targeted oral small molecule being developed for the treatment of patients with metastatic castratio...

Triumvira Immunologics, Inc.

Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T ...

Aragon Pharmaceuticals Inc.

Aragon Pharmaceuticals is a privately held small-molecule drug discovery company identifying breakthrough medicines for the treatment of hormonally driven cancers. These cancers are traditionally treated with anti-hormonal therapies but often become resistant, and follow-on therapies are largely ineffective. The company plans to initiate a clinical trial with its lead compound, ARN-509, in patient...

Triumvira Immunologics Inc.

Triumvira Immunologics, Inc. is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., a niche life-sciences investment bank, with the vision of developing novel T cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (C...

Novasite Pharmaceuticals, Inc

Novasite is a drug discovery company using structure-function relationships in validated G protein coupled receptor targets to find better GPCR modulating drugs.Novasite began as a majority-owned subsidiary of Applied Molecular Evolution, Inc. (“AME”), which was acquired by Eli Lilly in 2004 for $400M. Novasite is the exclusive licensee of AME molecular evolution technology, which the Company ...

Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin formulation, and hepatic (liver) glucose metabolism, the companyâ€...

Bio Balance, Inc.

BIO BALANCE INC., a New York corporation, founded in 1993, is engaged in studies of biomedical problems. The philosophy behind Bio Balance is that accurate descriptions of drug-receptor interactions will lead to the development of better pharmaceuticals. Bio Balance is devoted to a biophysical description of the initial receptor response. This should lead to improved pharmaceuticals and be an attr...

Kyto Biopharma Inc.

Kyto Biopharma Inc. is a Florida based biotechnology company operating from Toronto, Canada, developing monoclonal antibody therapies for the treatment of various forms of cancer. The Kyto research and development program is conducted under the scientific leadership of Dr. Edward Quadros of the State University of New York (SUNY Brooklyn), and Dr. Michael ...


More From BioPortfolio on "Glucose Dependent Insulinotropic Receptor Protein Coupled Receptor GPR119"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks